Back to Search
DEVALINGAM MAHALINGAM, M.D.
M.D.
Medical Oncology Physician
NPI: 1164650859IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
P1668(TX)036-142503(IL)
Education
OTHER
Class of 2000
Research & Publications (11)
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
PMID 19583815·J Cell Mol Med·2010
7-preclinical
Emerging drugs in the treatment of pancreatic cancer.
PMID 19466902·Expert Opin Emerg Drugs·2009
6-review
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
PMID 19381454·Target Oncol·2009
6-review
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
PMID 19381453·Target Oncol·2009
6-review
Targeting the mTOR pathway using deforolimus in cancer therapy.
PMID 19374536·Future Oncol·2009
6-review
Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines.
PMID 19352384·Br J Cancer·2009
8-other
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
PMID 19276284·Clin Cancer Res·2009
7-preclinical
Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
PMID 19160124·Leuk Lymphoma·2009
5-case
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
PMID 19117685·Cancer Treat Rev·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 645 N MICHIGAN AVE STE 1006
CHICAGO, IL 60611 - Phone
- (210) 413-1723
Quick Facts
- NPI
- 1164650859
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 26
- Publications
- 11
Are you this provider?
Claim Your Profile